Abstract

BIOLOGICS AND ANTIMICROBIAL RESISTANCE: A NEW FRONTIER

*Nidhi Singh, Prakash Chaudhary, Sayan Das, Shivangini Singh, Mansi Sinha and Dr. Nakul Gupta

ABSTRACT

This review explores the emerging potential of biologics, such as monoclonal antibodies and phage therapy, to address the global challenge of antimicrobial resistance (AMR). As the efficacy of traditional antibiotics declines due to bacterial resistance, biologics offer promising alternatives that employ targeted mechanisms to overcome resistant pathogens. By examining the applications, pharmacological implications, combination therapies, and regulatory challenges associated with biologics, this paper provides a comprehensive overview of their role in combating AMR and addresses the hurdles in their clinical implementation. AMR remains one of the biggest challenges that has threatened the success of traditional antibiotics, thus threatening public health and global economic stability. The failure of traditional antibiotics incombating resistant pathogens warrants urgent searches for alternative therapeutic approaches. In this review, we focus on biologics, which encompass monoclonal antibodies and bacteriophage therapy within a broad class of therapeutics as promising alternatives to combat AMR. Biologics use targeted mechanisms that neutralize pathogens without a detrimental impact on beneficial microbiota. They seem to be an extremely selective and flexible alternative to conventional treatments.

Keywords: AMR, mAbs, WHO, Antimicrobial, Bacteriophage.